[Outcomes of patients with small bowel carcinoma treated with appropriate chemotherapy selected on the basis of genetic analysis findings].
|
| Abstract |
Small bowel carcinoma is a rare tumor, for which a standardized chemotherapy regimen has not yet been established. Further, this tumor may belong to the group of Lynch syndrome-associated tumors, which are resistant to 5-fluorouracil (5-FU) -based chemotherapy. We investigated mismatch repair protein expression and K-ras gene mutation status in 8 patients with aggressive small bowel carcinoma and determined the chemotherapy regimen used in these patients. Immunohistochemical staining indicated normal mismatch repair protein expression in all surgical specimens. Of 8 patients, 4( 50%) had K-ras codon 12 mutations. Because small bowel carcinoma is not significantly associated with Lynch syndrome, 5-FU-based chemotherapy would be appropriate for the treatment of these patients. The prevalence of K-ras codon 12 mutations was relatively similar to that in patients with sporadic colorectal carcinoma, and the usefulness of anti- epidermal growth factor receptor (EGFR) antibody for the treatment of small bowel carcinoma should be evaluated in the future.
|
|---|---|
| Authors | Okihide Suzuki, Keiichiro Ishibashi, Hideko Imaizumi, Kunihiko Amano, Satoshi Hatano, Takeaki Matsuzawa, Tomohiko Ogita, Koki Kuwabara, Jun Sobajima, Toru Ishiguro, Morihiro Higashi, Minoru Fukuchi, Keisuke Kumamoto, Hiroyuki Baba, Yoichi Kumagai, Yoshitaka Tsuji, Junichi Tamaru, Erito Mochiki, Hideyuki Ishida |
| Journal | Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 40 Issue 12 Pg. 1714-6 (Nov 2013) ISSN: 0385-0684 [Print] Japan |
| PMID | 24393898 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!